
Sheet 1 of 2

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit 1655

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
~	AA	6,890,904	05/10/05	Wallner et al.			
~	AB	7,064,105	06/20/06	Joullié et al.			
~	AC						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
~	AD	WO 00/71135	11/30/00	WIPO				
~	AE	WO 01/35974	05/25/01	WIPO				
~	AF	WO 02/02596	01/10/02	WIPO				
~	AG	WO 02/30441	04/18/02	WIPO				
~	AH							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
~	AI	Bennett, J. Claude, and Fred Plum, eds. <i>Cecil Textbook of Medicine</i> , "Part XIV - Oncology", W. B. Saunders & Company, 20th Ed., Vol. 1, pp. 1004-1010 (1996).
~	AJ	Committee for Proprietary Medicinal Products (CPMP) - "Note for Guidance on Evaluation of Anticancer Medicinal Products in Man", <i>The European Agency for the Evaluation of Medicinal Products</i> , EMEA, London, England, CPMP/EWP/205/95 rev. 1 corr, 14 pages, (2001).
~	AK	DeVita, Jr., Vincent T, Samuel Hellman, and Steven A Rosenberg, eds. <i>Cancer: Principles and Practice of Oncology</i> , "Section 3 - Cancer of the Pancreas", Lippincott Williams & Wilkins, 7 th Ed., 7 pages, (2005).
~	AL	Draetta, Giulio et al., "Section V. Topics in Biology - Chapter 25. Cell Cycle Control and Cancer", <i>Annual Reports in Medicinal Chemistry</i> , pp. 241-248, 1996.
~	AM	Geldof et al., "Cytotoxicity and Neurocytotoxicity of New Marine Anticancer Agents Evaluated Using in Vitro Assays", <i>Cancer Chemother. Pharmacol.</i> ; 44 321-318, (1999).
~	AN	Hansen, Richard et al., "Continuous 5-Fluorouracil (5FU) Infusion in Carcinoma of the Pancreas: A Phase II Study", <i>American Journal of Medical Science</i> , 295:91-93, (1988).
~	AO	Kerbel, Robert S., "What is the Optimal Rodent Model for Anti-Tumor Drug Testing?", <i>Cancer and Metastasis Reviews</i> , 17: 301-304, (1999).
~	AP	O'Neil, Maryadele J., Ann Smith and Patricia E. Heckelman, eds. <i>The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals</i> , Merck & Co., Inc., 13 th Ed., page 1791, (2001).
~	AQ	Raymond, N. Ady-Vago et al., "25 th Congress of the European Society of Medicinal Oncology", Hamburg, Germany, 13-17 October 2000, reported in the <i>Annals of Oncology</i> , Kluwer Academic Publishers, Supplement 4 to Volume 11, Abstract 610PD, 2 pages, (2000).

Examiner Signature 	Date Considered 07/06/07
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14620-012US1	Application No. 09/622,433
	Applicant Bastian Nuyen et al.		
	Filing Date May 10, 2002	Group Art Unit 1655	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
<i>go</i>	AR	Tempero, Margaret, et al., <i>Clinical Practice Guidelines in Oncology – v.2.2006</i> – “Pancreatic Adenocarcinoma” National Comprehensive Cancer Network, http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf , 41 pages, (2006).
<i>by</i>	AS	Urdiales et al., “Antiproliferative Effect of Dehydroididemnin B (DDB), a Depsipeptide Isolated from Mediterranean Tunicates”, <i>Cancer Letters</i> , 102:31-37, (1996).
<i>so</i>	AT	U.S. National Cancer Institute, U.S. National Institutes of Health, www.cancer.gov , “FactSheet”, 6 pages, http://www.cancer.gov/cancertopics/factsheet/information/clinical-trials
<i>AV</i>	AU	U.S. National Cancer Institute, U.S. National Institutes of Health, www.cancer.gov , “Pancreatic Cancer (PDQ®): Treatment”, 3 pages, http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/healthprofessional
<i>Red</i>	AV	Van-Boxtel, C. J., B. Santoso and I. R. Edwards, eds. <i>Drug Benefits and Risks: International Textbook of Clinical Pharmacology</i> , “Drug Development”, Chapter 9, pp. 91-102, (2001).

Examiner Signature <i>[Signature]</i>	Date Considered <i>09/06/07</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	